Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-28T00:27:20.016Z Has data issue: false hasContentIssue false
  • English
  • Français

Bone mineral density and general health of long-term residential psychiatric inpatients

Published online by Cambridge University Press:  13 June 2014

Brian Hallahan ,
Declan Lyons  and
Patrick Doyle
Brian Hallahan*
Affiliation:
University Hospital Galwayand National University of Ireland, Galway, Ireland
Declan Lyons
Affiliation:
Mid-Western Regional Hospital, Limerick, Ireland
Patrick Doyle
Affiliation:
Limerick Mental Health Services, Ireland
*
Correspondence E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective: The aim of this study was to determine the rates of osteopenia and osteoporosis and other general health problems in a long-stay male psychiatric unit.

Method: All 15 patients underwent a semi-structured clinical interview and a full physical examination including calculation of Body Mass Index, central obesity (abdominal circumference) and blood pressure measurement. All patients had blood sampling examining FBC, U&E, LFTs, TFTs, PSA, prolactin, lipid profile and glucose. The rates of metabolic syndrome were calculated according to the International Diabetes Federation consensus worldwide definition. Bone mineral density was determined in the lumbar vertebrae and left hip by DEXA scanning.

Results: The prevalence of osteopenia or osteoporosis was 46%, and bone mineral density was inversely correlated with serum prolactin levels (r = -0.595, p = 0.041) and chlorpromazine equivalence (r = -0.645, p = 0.017). The prevalence of obesity was 53%, while central obesity was present in 87% of patients. Metabolic Syndrome was present in 27% of patients.

Conclusions: More attention should be given to diagnosing and treating osteopenia and osteoporosis in patients on long-term antipsychotic agents and preventative measures should form part of any treatment regime in these individuals. Frequent input from dietitians should also be available for long-stay psychiatric inpatients to reduce the prevalence of obesity.

Keywords

DEXABone mineral densityOsteoporosisObesityMetabolic syndrome
Type
Original Papers
Information
Irish Journal of Psychological Medicine , Volume 25 , Issue 3 , September 2008 , pp. 95 - 99
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Barraclough, EC, Harris, B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173:11–53.Google Scholar
2.Cormac, I, Martin, D, Ferriter, M. Improving the physical health of long-stay psychiatric patients. Adv Psychiatr Treat 2004; 10:107–15.CrossRefGoogle Scholar
3.Brown, S, Barraclough, B, Inskip, H. Cause of the excess mortality in schizophrenia. Br J Psychiatry 2000; 177: 212–7.CrossRefGoogle ScholarPubMed
4. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome.2006. IDF, Avenue Emile de Mot 19, B-1000, Brussels, Belguim.Google Scholar
5.Pouliot, MCet al.Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73: 460–8.CrossRefGoogle ScholarPubMed
6.Ohlson, LOet al.The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985; 34: 1055–8.CrossRefGoogle Scholar
7.O'Brien, S, Devitt, E, Ahmed, M, McDonald, C high prevalence of risk factors for physical illness in a long-stay psychiatric unit. Ir J Psychol Med 2007; 24: 55–8.CrossRefGoogle Scholar
8.Tirupati, S, Chua, LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust NZ Psychiatry 2007; 41: 606–10.CrossRefGoogle Scholar
9. World Health Organisation Study Group 1994. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva: WHO Technical report Series 1994; no. 843: 1-12.Google Scholar
10.Dickson, R, Seeman, M, Corenblum, B. Hormonal side effects in women: typical versus antipsychotic treatment. J Clin Psychiatry 2000; 61(Suppl. 3): 10–5.Google ScholarPubMed
11.Taylor, D, Paton, C, Kerwin, R. The Maudsley Prescribing Guidelines (9th ed). London: Informs Healthcare, 2007.CrossRefGoogle Scholar
12.Naidoo, U, Goff, DC, Kilbanski, A. Hyperprolactinaemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28(Suppl. 2): 97–108.CrossRefGoogle ScholarPubMed
13.Wieck, A, Haddad, PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003; 182: 199–204.CrossRefGoogle ScholarPubMed
14.Schlecter, JA, Sherman, B, Martin, R. Bone density in amenorrheic women with and without hyperprolactinaemia. J Clin End Met 1983; 56:1120–3.CrossRefGoogle Scholar
15.Meaney, AM, Smith, S, Howes, OD, O'Brien, OD, Murray, RM, O'Keane, V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184:503–8.CrossRefGoogle Scholar
16.Hummer, Met al.Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005; 162; 162–7.CrossRefGoogle ScholarPubMed
17.Barondess, DA, Nelson, DA, Schlaen, SE. Whole body bone, fat, and lean mass in black and white men. J Bone Miner Res 1997; 12: 967–71.CrossRefGoogle ScholarPubMed
18.Wagner, DR, Heyward, VH. Measures of body composition in blacks and whites: A comparative review. Am J Clin Nutr 2000; 71:1392–402.CrossRefGoogle ScholarPubMed
19.de Leon, J. Polydypsia – a study in a long-term psychiatric unit. Eur Arch Psychiatry Clin Neurosci 2003; 253: 37–9.CrossRefGoogle Scholar
20.Delva, NJet al.Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydypsia. Biol Psychiatry 1989; 26: 781–93.CrossRefGoogle Scholar
21.Leucht, S, Burkard, T, Henderson, J, Maj, M, Sartorius, N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007; 116: 317–33.CrossRefGoogle ScholarPubMed
22.Boiling, EP. Secondary osteoporosis: underlying disease and the risk of glucocorticoid-induced osteoporosis. Clin Ther 2004; 26: 1–14.CrossRefGoogle Scholar
23.Pearce, G, Tabensky, DA, Delmas, PD, Baker, HW, Seeman, E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998; 83: 801–6.CrossRefGoogle ScholarPubMed
24.Khan, MN, Khan, AA, Cancer treatment-related bone loss: a review and synthesis of the literature. Curr Oncol 2008; 15(Suppl 1): S30–40.CrossRefGoogle ScholarPubMed
25.Petty, SJet al.Effect of antiepileptic medication on bone mineral measures. Neurology 2005; 65: 1358–65.CrossRefGoogle ScholarPubMed
26.Samaniego, EA, Sheth, RD. Consequences of epilepsy and antiepileptic medications. Semin Pediatr Neurol Bone 2007; 14: 196–200.CrossRefGoogle ScholarPubMed
27.American Psychiatric Association. Diagnostic and Statistical manual of Mental Disorders (4th ed) (DSM-IV). Washington, DC 1994.Google Scholar
28.Lehman, AF, Steinwachs, DM. At issue; Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1–10.CrossRefGoogle Scholar
29.Woods, SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663–7.CrossRefGoogle ScholarPubMed
30.Cockroft, DW, Gault, MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31–41.CrossRefGoogle Scholar
31.Perez-Iglesias, Ret al.A 12 week randomised clinical trial to evaluate metabolic changes in drug-naïve, first-episode psychosis patients treated with haloperidol, olanzapine, or risperdone. J Cin Psychiatry 2007; 68:1733–40.Google ScholarPubMed
32.Villegas, R, Perry, IJ, Creagh, D, Hinchion, R, O'Halloran, D. Prevalence of the metabolic syndrome in middle-aged men and women. Diabetes Care 2003; 26: 3198–9.CrossRefGoogle ScholarPubMed
33.Lips, P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly; consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22:477–501.CrossRefGoogle ScholarPubMed
34.Demirbag, D, Ozdemir, F, Ture, M. Effects of coffee consumption and smoking habits on bone mineral density. Rheumatol Int 2006; 26: 530–5.CrossRefGoogle ScholarPubMed
35.Kanis, JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929–36.CrossRefGoogle ScholarPubMed
36.Kanis, JA. (WHO Study Group). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int 1994; 4: 268–81.CrossRefGoogle ScholarPubMed
37.Kanis, JA, Johnell, O, Oden, A, DeLac, C, Jonsson, B, Dawson, A. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 2002; 30:251–8.CrossRefGoogle ScholarPubMed
38.Marder, SRet al.Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334–49.CrossRefGoogle ScholarPubMed
39.American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists et al.Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65; 267–72.CrossRefGoogle Scholar
40.Meyer, JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001; 62 (Suppl 27): 27–34.Google ScholarPubMed